Cyberonics developed the Vagal Nerve Stimulator (VNS) as the first implantable device for the treatment of partial refractory epilepsy. Cita helped to launch the product first in Europe and then domestically upon FDA approval. The launch campaign for physicians included a master sales aid, tradeshow graphics, and advertisements as well as billing and reimbursement guides.
A key component to the launch was a surgical video to educate neurosurgeons on the implant technique for this unique device. The training program included interviews with leading neurosurgeons, implant techniques from actual cases, and the creation of medical illustrations and animation to depict the mechanism of action.
Today, more than 65,000 patients in over 24 countries have been implanted with the VNS Therapy device.